RT Journal Article
SR Electronic
T1 RET Inhibitor Prompts Roche–Blueprint Alliance
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
DO 10.1158/2159-8290.CD-NB2020-070
YR 2020
UL http://cancerdiscovery.aacrjournals.org/content/early/2020/07/23/2159-8290.CD-NB2020-070.abstract
AB Blueprint Medicines entered into a strategic partnership with Roche to jointly develop and commercialize pralsetinib, a targeted agent for RET-driven malignancies. If pralsetinib is approved, Roche's vast commercial network and diagnostic abilities could help the drug compete against another RET inhibitor, Eli Lilly's selpercatinib, which was approved in May.